Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-13
2005-12-13
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S367000
Reexamination Certificate
active
06974818
ABSTRACT:
A compound of formula:(wherein X is O or S and R1, R3, R4, and R5are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Thiadiazolylpiperazine Compound”), pharmaceutical compositions comprising a Thiadiazolylpiperazine Compound, and methods for treating or preventing pain in a patient comprising administering to a patient in need thereof an effective amount of a Thiadiazolylpiperazine Compound are disclosed.
REFERENCES:
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5762925 (1998-06-01), Sagen
patent: 6109269 (2000-08-01), Rise et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6239267 (2001-05-01), Duckworth et al.
patent: 6335180 (2002-01-01), Julius et al.
patent: 6406908 (2002-06-01), McIntyre et al.
patent: 2003/0153596 (2003-08-01), Suh et al.
patent: 2003/0158188 (2003-08-01), Lee et al.
patent: 2003/0158198 (2003-08-01), Lee et al.
patent: WO 02/08221 (2002-01-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 03/022809 (2003-03-01), None
patent: WO 03/062209 (2003-07-01), None
patent: WO 03/068749 (2003-08-01), None
Bevan, S. et al, Current Opinion in CPNS Investigational Drugs, 2000, vol. 2, 178-185.
Wermuth, C.G. et al, Glossary of Terms Used in Medicinal Chemistry, International Union of Pure and Applied Chemistry [retrieved on Jan. 21, 2002]. dated 1998 Retreived from the Internet <http://www.chem.qmw.ac.uk/iupac/medchem/ah.html>.
Pomonis, J.D. et al, J. Pharmacology and Exp. Ther., 2003, 306, 387-393.
Attila Tóth 1, Peter M. Blumberg, Zili Chen, and Alan P. Kozikowski, Mol Pharmacol 65:282-291, 2004.
Yun Wang, 1 Tamas Szabo, Jacqueline D. Welter, Attila Toth, Richard Tran, Jiyoun Lee, Sang Uk Kang, Young-Ger Suh, Peter M. Blumberg, and Jeewoo Lee, Mol Pharmacol 62:947-956, 2002.
K. Walker et al., “Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain,” Neuropharmacology 40:1-9, 2000.
A. Dogrul et al., Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR5) antagonist, in experimental neuropathic pain in rats, Neuroscience Letters 292(2):115-118, 2000.
K.W. Foley, “Pain” Cecil Textbook of Medicine, pp. 100-107, 1996.
R.M. Resnick, “Urinary Incontinence,” Lancet 346:94-99, 1995.
A.R. Herzo et al., “Urinary Incontinence: Medical and Psychosocial Aspects,”Anu. Rev. Gerontol. Geriatr. 9:74-119, 1989.
A.W. Wein, “Pharmacology of Incontinence,” Urologic Clinics of North America, 22(3):557-577, 1995.
R.M. Levin et al., “Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder,” The Journal of Urology, 128:396-398, 1982.
R.D. Cooke, “Glycopyrrolate in bladder dysfunction,” SA Medical Journal, 63:3, 1983.
R.K. Mirakhur et al., “Glycopyrrolate: pharmacology and clinical use,” Anaesthesia 38:1195-1204, 1983.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 345-350, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 352-355, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 496-500, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 525-526, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 528-530, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 530-532, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 631-634, 1997.
Goodman ane Gillman's The Pharmaceutical Basis of Therapeutics 506, 901-915 (J. Hardman and L. Limbird eds., 9thed. 1996).
E. Tatarczynska et al., Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist, British Journal of Pharmaology 132(7):1423-1430, 2001.
P.J.M. Will et al., “Novel allosteric antagonists shed light on mglu5receptors and CNS disorders,” Trends in Pharmacological Sciences, 22(7):331-337, 2001.
K. Ossowska et al., “Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats,” Neuropharmacoloyg 41:413-420, 2001.
C. Chiamulera et al., “Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant rice,” Nature Neuroscience 4(9):873-874, 2001.
R. Wrigglesworth and C. Walpole, “Capsaicin-like Agonists,”Drugs of the Future, 23(5):531-38 (1998).
A. Szallash and P. Blumberg, “Vanilloid (Capsaicin) Receptors and Mechanisma,”Pharmacology Reviews, 51(2):159-211 (1999).
S. Bevan and P. McIntyre, “Vanilloid Receptors: Pivotal Molecules in Nocciception,”Current Opinions in CPNS Investigational Drugs, 2(2):178-85 (2000).
Kyle Donald J.
Sun Qun
Euro-Celtique S.A.
McKenzie Thomas C.
LandOfFree
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3509389